GT Biopharma (GTBP) executive compensation, 2026 proxy

Michael Breen, Chairman, Chief Executive Officer, and President, was paid $1.7M in 2025, up 46% from $1.2M the year before.

Filed
July 2, 2026
Annual meeting
August 14, 2026
Pay year
2025
Named executives
2
CEO total pay
$1.7M+46% vs prior year
CEO target bonus
75%Breen employment agreement
CFO bonus maximum
40%Base salary percentage
CEO option award
$342,000300,000 shares
CFO option award
$113,000100,000 shares
CEO PTO payout
$75,9962025 other compensation

How Breen was paid

$1.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary37%Bonus34%Option awards20%All other compensation9%

Named executive officers

ExecutiveTotal
Michael BreenChairman, Chief Executive Officer, and President$1,727,646
Alan UrbanChief Financial Officer$739,310

What changed and why

  • $1.7M$1,727,646 was CEO total compensation in 2025 versus $1,186,972 in 2024.
  • $342K$342,000 CEO option award was granted in 2025 for 300,000 common shares.
  • $75,996$75,996 of CEO other compensation represented paid time off payout in 2025.
  • 75%75% was the CEO’s target annual bonus under his employment agreement.
  • $113K$113,000 CFO option award was granted in 2025 for 100,000 common shares.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.